These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 32423125)

  • 41. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents.
    Lordan R; Tsoupras A; Zabetakis I
    Blood Rev; 2021 Jan; 45():100694. PubMed ID: 32340775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating miRNAs as biomarkers in cardiovascular diseases.
    Kaneto CM; Nascimento JS; Prado MSJG; Mendonça LSO
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2234-2243. PubMed ID: 30915771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia.
    Tran JQD; Pedersen OH; Larsen ML; Grove EL; Kristensen SD; Hvas AM; Nissen PH
    Platelets; 2020; 31(3):365-372. PubMed ID: 31240987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.
    Garabet L; Ghanima W; Rangberg A; Teruel-Montoya R; Martinez C; Lozano ML; Nystrand CF; Bussel JB; Sandset PM; Jonassen CM
    Platelets; 2020; 31(2):198-205. PubMed ID: 30885035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases.
    Kondkar AA; Abu-Amero KK
    Biomed Res Int; 2015; 2015():821823. PubMed ID: 25710029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from micro-array profiling in a cohort of 60 patients.
    Stratz C; Nührenberg T; Fiebich BL; Amann M; Kumar A; Binder H; Hoffmann I; Valina C; Hochholzer W; Trenk D; Neumann FJ
    Thromb Haemost; 2014 May; 111(5):902-11. PubMed ID: 24352417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring.
    Procyk G; Klimczak-Tomaniak D; Sygitowicz G; Tomaniak M
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNAs as biomarkers for clinical studies.
    Pogribny IP
    Exp Biol Med (Maywood); 2018 Feb; 243(3):283-290. PubMed ID: 28914096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients.
    Muñoz-Esquerre M; Ferreiro JL; Huertas D; Marcano AL; López-Sánchez M; Roura G; Gómez-Hospital JA; Dorca J; Cequier A; Santos S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():141-148. PubMed ID: 29343953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.
    Marcone S; Dervin F; Fitzgerald DJ
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S323-31. PubMed ID: 26149042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression.
    Gidlöf O; van der Brug M; Ohman J; Gilje P; Olde B; Wahlestedt C; Erlinge D
    Blood; 2013 May; 121(19):3908-17, S1-26. PubMed ID: 23493781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation.
    Gatsiou A; Boeckel JN; Randriamboavonjy V; Stellos K
    Curr Vasc Pharmacol; 2012 Sep; 10(5):524-31. PubMed ID: 22338566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
    Vallés J; Moscardo A; Madrid I; Santos MT
    Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy.
    Ntelios D; Georgiou E; Alexouda S; Malousi A; Efthimiadis G; Tzimagiorgis G
    Heart Fail Rev; 2022 Jan; 27(1):281-294. PubMed ID: 33656618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-Based Diagnosis and Therapy.
    Ho PTB; Clark IM; Le LTT
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients.
    Escate R; Padró T; Suades R; Camino S; Muñiz O; Diaz-Diaz JL; Sionis A; Mata P; Badimon L
    Cardiovasc Res; 2021 Jan; 117(1):109-122. PubMed ID: 32061123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelet microRNAs: From platelet biology to possible disease biomarkers and therapeutic targets.
    Stakos DA; Gatsiou A; Stamatelopoulos K; Tselepis AD; Stellos K
    Platelets; 2013; 24(8):579-89. PubMed ID: 22994623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance.
    Lin S; Xu X; Hu H; Cheng J; Chen R; Hu Y; Chen X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00751. PubMed ID: 33724726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-efficiency unassisted transfection of platelets with naked double-stranded miRNAs modulates signal-activated translation and platelet function.
    Lazar S; Wurtzel JGT; Chen X; Ma P; Goldfinger LE
    Platelets; 2021 Aug; 32(6):794-806. PubMed ID: 32838617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.